MetaCap

Alzamend Neuro (ALZN) vs Lantern Pharma (LTRN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Lantern Pharma is the larger company by market cap ($3.9 million vs $3.7 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ALZN-43.37%LTRN-73.08%
+17%-30%-77%
Oct 7, 20261 yearNov 20, 2026
ALZN-42.10%LTRN-69.85%
+9%-32%-74%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ALZN versus LTRN key metrics
MetricALZNLTRN
Share price$0.7758$0.245
Market cap$3.74M$3.89M
1-day change-23.94%-13.73%
YTD return—-91.91%
1-year return—-91.89%
5-year return—-97.27%
EPS (TTM)$-2.30$-1.44
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-8.77M$-17.12M
52-week high$2.54$4.34
52-week low$0.754$0.2286
Distance from 52-week high-69.40%-94.35%
Analyst consensusnonenone
Avg. price target upside+3251.38%+7042.86%
Average volume70.27K249.66K
Shares outstanding4.83M15.89M
Employees416
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Alzamend Neuro

ALZN stock →

Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.

Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees

About Lantern Pharma

LTRN stock →

Lantern Pharma Inc. focuses on the discovery and development of oncology drug in India.

Health Care · Biotechnology: Pharmaceutical Preparations · 16 employees

ALZN vs LTRN FAQ

Which is bigger, Alzamend Neuro or Lantern Pharma?

Lantern Pharma (LTRN) is larger, with a market capitalization of $3.89M compared with $3.74M for Alzamend Neuro (ALZN).

Are Alzamend Neuro and Lantern Pharma in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons